As of 2026-05-27, the Relative Valuation of HPGC Renmintongtai Pharmaceutical Corp (600829.SS) is 4.29 CNY. This relative valuation is based on P/E multiples. With the latest stock price at 8.75 CNY, the upside of HPGC Renmintongtai Pharmaceutical Corp based on Relative Valuation is -50.9%.
The range of the Relative Valuation is 2.58 - 6.63 CNY.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 18.1x | 14.2x |
| Forward P/E multiples | 9.2x - 12.9x | 10.2x |
| Fair Price | 2.58 - 6.63 | 4.29 |
| Upside | -70.5% - -24.2% | -50.9% |
| Date | P/E |
| 2026-05-25 | 37.69 |
| 2026-05-22 | 37.99 |
| 2026-05-21 | 37.31 |
| 2026-05-20 | 38.67 |
| 2026-05-19 | 39.35 |
| 2026-05-18 | 39.01 |
| 2026-05-15 | 39.48 |
| 2026-05-14 | 40.24 |
| 2026-05-13 | 41.47 |
| 2026-05-12 | 41.90 |
| 2026-05-11 | 42.58 |
| 2026-05-08 | 41.73 |
| 2026-05-07 | 41.69 |
| 2026-05-06 | 41.86 |
| 2026-04-30 | 41.30 |
| 2026-04-29 | 41.13 |
| 2026-04-28 | 40.96 |
| 2026-04-27 | 41.26 |
| 2026-04-24 | 40.84 |
| 2026-04-23 | 41.09 |
| 2026-04-22 | 41.26 |
| 2026-04-21 | 41.69 |
| 2026-04-20 | 42.15 |
| 2026-04-17 | 41.86 |
| 2026-04-16 | 42.37 |
| 2026-04-15 | 43.77 |
| 2026-04-14 | 41.60 |
| 2026-04-13 | 41.90 |
| 2026-04-10 | 44.66 |
| 2026-04-09 | 44.32 |
| 2026-04-08 | 46.70 |
| 2026-04-07 | 49.59 |
| 2026-04-03 | 47.17 |
| 2026-04-02 | 48.02 |
| 2026-04-01 | 43.90 |
| 2026-03-31 | 43.30 |
| 2026-03-30 | 43.47 |
| 2026-03-27 | 42.58 |
| 2026-03-26 | 41.43 |
| 2026-03-25 | 42.03 |
| 2026-03-24 | 41.47 |
| 2026-03-23 | 39.77 |
| 2026-03-20 | 41.47 |
| 2026-03-19 | 42.32 |
| 2026-03-18 | 43.47 |
| 2026-03-17 | 42.79 |
| 2026-03-16 | 43.47 |
| 2026-03-13 | 43.09 |
| 2026-03-12 | 43.09 |
| 2026-03-11 | 43.90 |